A carregar...
A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation
CML therapy has improved dramatically with the development of tyrosine kinase inhibitors (TKIs). Prior to the TKI era, we conducted two trials of alpha-interferon (IFN) for post-transplant hematologic and cytogenetic relapse. The complete cytogenetic response rate was 33% and 57% respectively. This...
Na minha lista:
| Publicado no: | Leuk Lymphoma |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6813875/ https://ncbi.nlm.nih.gov/pubmed/31014151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1605508 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|